Orphenadrine is a drug acting on multiple targets, including muscarinic, histaminic, and NMDA receptors. It is used in the treatment of Parkinson's disease and in musculoskeletal disorders. It is also used as an analgesic, although its mechanism of action is still unknown. Both physiological and pharmacological results have demonstrated a critical role for voltage-gated sodium channels in many types of chronic pain syndromes. We tested the hypothesis that orphenadrine may block voltage-gated sodium channels. By using patch-clamp experiments, we evaluated the effects of the drug on whole-cell sodium currents in HEK293 cells expressing the skeletal muscle (Nav1.4), cardiac (Nav1.5) and neuronal (Nav1.1 and Nav1.7) subtypes of human sodium channels, as well as on whole-cell tetrodotoxin (TTX)-resistant sodium currents likely conducted by Nav1.8 and Nav1.9 channel subtypes in primary culture of rat DRG sensory neurons. The results indicate that orphenadrine inhibits sodium channels in a concentration-, voltage-and frequency-dependent manner. By using site-directed mutagenesis, we further show that orphenadrine binds to the same receptor as the local anesthetics. Orphenadrine affinities for resting and inactivated sodium channels were higher compared to those of known sodium channels blockers, such as mexiletine and flecainide. Low, clinically relevant orphenadrine concentration produces a significant block of Nav1.7, Nav1.8, and Nav1.9 channels, which are critical for experiencing pain sensations, indicating a role for sodium channel blockade in the clinical efficacy of orphenadrine as analgesic compound. On the other hand, block of Nav1.1 and Nav1.5 may contribute to the proconvulsive and proarrhythmic adverse reactions, especially observed during overdose. Ó
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Introduction
Orphenadrine is an anticholinergic agent used mainly in the treatment of Parkinson's disease to alleviate some of the troublesome symptoms of the disease, especially the involuntary resting tremor [44, 45] . In addition to this use, the drug has a long history in the clinics as a muscle relaxant [19] . The mechanism of action for such effect remains unclear, but may be related in part to sedative effects; orphenadrine exerts unspecific antagonist activity at the phencyclidine binding site of N-methyl-D-aspartate (NMDA) receptors, one of the subtypes of glutamate receptors [24] . A study reported that orphenadrine is able to protect cultured cerebellar neurons from excitotoxicity following direct exposure of neurons [17] .
Orphenadrine is used also as an analgesic both alone and in association with non-steroidal anti-inflammatory drugs [21] . In a human model of capsaicin-dependent inflammatory pain obtained with laser somatosensory-evoked potentials, orphenadrine citrate was able to exert an analgesic/anti-hyperalgesic effect in a low dose (30 mg/day), which was predominantly due to central/spinal mechanisms [42] . A central action of orphenadrine was thus proposed, but the detailed mechanisms are unknown.
Orphenadrine is a monomethylated derivative of diphenhydramine, an antihistaminic drug. Since histamine plays an important role in pain processes, it is possible that the analgesic action of orphenadrine may be related to histamine antagonism. However, diphenhydramine was also shown to block voltage-gated sodium channels [22] , suggesting that other pharmacological properties may contribute to antinociceptive effects of orphenadrine. Both physiological and pharmacological evidence have demonstrated a critical role for voltage-gated sodium channels in many types of chronic pain syndromes, because these channels play a fundamental role in the excitability of neurons in the central and
